ABSTRACT Identifying interaction between drug and protein is a crucial challenge in drug discovery, which can lead the researchers to develop novel drug compounds or new target proteins for the existing drugs. The determination of drug-target interactions (DTIs) is an extremely time-consuming, costly, and tedious task with wet-lab experiments. To date, multiple computational techniques have been presented to simplify the drug discovery process, but a huge number of interactions are still undiscovered. Furthermore, a class imbalance is a critical challenge regarding this experiment which can significantly degrade the classification accuracy that has not been effectively addressed yet. In this paper, we proposed a novel high-throughput computational model, called iDTi-CSsmoteB, for identification of DTIs based on drug chemical structures and protein sequences. More specifically, the protein sequence is extracted through position-specific scoring matrix (PSSM)-Bigram, amphiphilic pseudo amino acid composition (AM-PseAAC) and dipeptide PseAAC descriptors which represents evolutionary and sequence information. The drug chemical structure is represented as a molecular substructure fingerprint (MSF) which describes the existence of the functional fragments or groups. Finally, we used the over-sampling SMOTE technique to overcome the imbalance issue of the datasets and applied XGBoost algorithm as a classifier to predict DTIs. To evaluate the performance of iDTi-CSsmoteB, several experiments have been conducted on four benchmark datasets, namely, enzyme, ion channel, GPCR, and nuclear receptor based on fivefold cross validation. The experimental analysis exhibits that our model outperforms similar methods in terms of area under the ROC (auROC) curve. In addition, our achieved results indicate the effectiveness of the feature extraction techniques, balancing methods, and classifier for predicting the DTIs which can provide substance for new drug development. iDTi-CSsmoteB webserver is available online at http://idticssmoteb-uestc.me/.
I. INTRODUCTION
In the post-genomic era, many of the interactions between drug compounds and pharmacological targets are unknown.
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The determination of interactions within drugs and targets is an important area in drug discovery research which plays a significant role in developing new targets for existing drugs or discovering novel drug candidates for current targets and to divulge their therapeutic schemes or side effects [1] - [3] . In past years, much concern has been imposed to identify drug-target interactions (DTIs) using wet-lab experiments. Based on the Food and Drug Administrations (FDA) analytical data [4] , few of the drug candidates get permission to reach the market in each year whereas maximum drugs reject during clinical tests due to the cause of inadmissible side effects or toxicity [5] . In addition, the average cost in developing a successful novel drug compound is approximately $1.8 billion, and it takes around 10 years [6] . Since, wet-lab experiments are costly, researchers are highly motivated to develop computational models for efficient prediction of DTIs which provides complementary and supporting information for further research [7] , [8] . Due to the rapid expansion of drugs and genomes heterogeneous data, a number of publicly available online databases focusing on faster drug development have been established such as DrugBank [9] , KEGG [10] , ChEMBL [11] , TTD [12] , [13] and STITCH [14] .
Over the past several years, a variety of computational approaches have been proposed for predicting and analyzing DTIs based on available interaction data [15] - [20] . In general, the traditional computational methods are divided into three categories: ligand-based method, docking simulation method, and chemogenomic method. The ligand virtual screening methods establish relationships based on the structural similarity between the target proteins' ligands in a classic QSAR (Quantitative Structure Activity Relationship) framework [21] . For instance, Keiser et al. proposed an approach to predict new molecular targets based upon the 2D chemical similarity of ligands [17] . Consequently, Campillos et al. [22] adopted similarities of phenotypic sideeffects to infer molecular functions from drugs and targets. However, the ligand-based methods demonstrate poor performance and low effectiveness for target proteins due to the insufficient known ligands. The docking simulation based method is a useful and powerful molecular modeling technique where protein and drug molecule bound together by dynamic simulation in the structure of stable complex [18] - [20] . However, this method has limitation that it requires three-dimensional (3D) structures of proteins for simulation. Finding 3D structures of the proteins is a timeconsuming process which is performed through experimental techniques i.e. X-ray Crystallography and NMR. Moreover, it is very complicated to obtain 3D structure for GPCRs and ion channel datasets.
To tackle the above limitations of traditional approaches, chemogenomic method [23] have been performed successfully to predict DTIs by combining the chemical structure of drug molecules and the sequence information of target proteins. This method can be classified as machine learning [24] (supervised methods [25] , [26] and semi-supervised methods [27] , [28] ), network methods [29] , [30] and matrix factorization theory [31] - [33] . The machine learning based techniques have developed predictive models based on discriminative features or similarity matrices between drug molecules and target proteins where experimentally validated pairs are used as standard datasets. Different supervised learning algorithms such as deep learning [34] , SVM [35] , k-nearest neighbor [36] , fuzzy logic [37] and random forest [38] have been utilized to address this task on various types of datasets. Yamanishi et al. [24] first introduced a unified space model to formalize the inference of the drug and target prediction as a supervised classification problem for a bipartite graph. Subsequently, the same authors [39] investigated the association among chemical space and pharmacological space with the drug-target networks topology and unitized distance learning algorithm. The purpose of their proposed method is to infer the unknown drug-target similarity interactions from the potential pharmacological effect to an integrated framework of supervised learning. Another supervised learning approach [25] have been developed to address two most important issues such as similarity measure and missing interactions. To solve the similarity measure issue, authors introduce a non-structural and functional-category-based similarity metric for drugs and targets. Moreover, the proposed 'super-target' concept manages the huge volume of missing interactions between drugs and targets in the prediction which have great effect on the performance of the predictive model. Some methods [27] , [28] further adopted the semi-supervised techniques to identify the potential noninteraction pairs from labeled and unlabeled drug-target interactions by investigating the coverage index and rank coherence.
Determining new interaction is significant not only for discovering novel drugs, but also for expanding genomic information by understanding the drugs actions and their functions. Based on the heterogeneous network, Seal et al. [40] applied a RWR technique to identify DTIs from DrugBank datasets and investigated the efficacy of the approach under the parameter variation. According to the similarity network of genomic data, Hao et al. [41] proposed nonlinear kernel fusion method for predicting DTIs using the combination of different kernels; and integrated the regularized least squares technique with kernel fusion to increase the effectiveness of the method.
Another work, Gönen [16] employed matrix factorization, dimensionality reduction and binary classification techniques to develop a Bayesian formulation method, called KBMF2K, for identifying DTIs. Further, some of the prominent matrix factorization works have been proposed such as KronRLS [31] , TMF [33] and NRLMF [32] to effectively minimize drawbacks of the traditional problems. In [31] , [33] , the authors considered four scenarios of screening DTI, including S1-drug repositioning (existing drugs and targets), S2-phenotypic screening (new drugs and existing targets), S3-target-based screening (existing drugs and new target) and S4-novel drug-protein pairs (new drugs and targets). Most importantly, few of the existing approaches can handle the most challenging scenario-S4 and provide explicit information of the interactions mechanism, where the model attends in discovering the pairwise interacting samples among newly designed drugs and proteins.
Since the number of non-interacting pairs are larger than interacting pairs in the experimental datasets, called imbalanced data, can reduce the prediction performance. Ezzat et al. [42] proposed an ensemble learning method to address the class imbalance problem. They classified the class imbalance issue into two sub-sections: between-class and within-class imbalance. Recently, Huang et al. [43] presented extremely randomized trees approach to predict DTIs. The substructure fingerprint vector is employed to represent drug molecules and the Pseudo-SMR (pseudo substitution matrix) is encoded from the protein sequences. Another similar work, Wang et al. [44] extracted evolutionary information from protein sequences and the structural features from drug molecules; a rotation forest classifier is independently utilized for developing predictive model. A probability theory based statistical technique, called Auto Covariance (AC) was firstly utilized by these authors in the protein sequence for calculating the correlation of two residues. In another recent work, structure based features model called idti-esboost has been proposed by Rayhan et al. [45] which utilized the cluster under sampling method to balance the benchmark datasets. This method exploit the evolutionary information and structural properties of protein such as torsional angles composition, torsional angles bigram along with AdaBoost algorithm. In [46] , the authors developed a new classification algorithm namely discriminative vector machine. The proposed method used PSSM and LBP (local binary pattern) to extract the protein sequences, the drug compound utilized substructure fingerprint method to encode the drug chemical structure.
To mitigate the influence of noise, the authors also applied PCA (principal component analysis) to encode discriminative properties from drug and proteins datasets. Although, previous methods provided substantial improvement in the results, however, there still exists some drawbacks in predicting DTIs: (i) none of the aforementioned approaches incorporated sequence information based feature methods (e.g., AM-PseAAC) for identification of DTIs; (ii) the existing approaches did not effectively addressed the imbalance issue; (iii) until now, the previous methods did not provide satisfactory prediction performance for all the four benchmark datasets.
To overcome the above limitations and enhance the prediction efficiency, this article proposes a novel computational method for identifying the drug target interactions using SMOTE technique [47] with XGBoost classifier. We utilize structural properties of drug, and evolutionary information and sequence information of proteins for prediction. Firstly, the protein sequences are transformed into numerical form using feature extraction methods called PSSM-Bigram, DP-PseAAC and AM-PseAAC. For a drug compound, a novel PubChem substructure fingerprint has been utilized to describe its chemical structure information which signifies the presence of certain fragments. Afterwards, the drug-target features are combined together to construct the experimental datasets where the interacting drug-target pairs are represented as positive samples and non-interacting drug-target pairs are represented as negative samples. In this work, we used two data balancing methods including random sampling and over-sampling SMOTE with XGBoost classifier in order to construct the predictive model and evaluate the effectiveness of the balancing techniques. As a result, our newly developed iDTi-CSsmoteB has shown magnificent advantage to handle the biasness issue and provides superior prediction performance on a widely used gold standard drug-target datasets. Our proposed iDTi-CSsmoteB is illustrated in Figure 1 .
The rest part of the paper is structured as follows: Section II describes detail of the materials and methods we employed in this paper; Section III highlights the experimental results and discussion and finally conclusion is drawn in the Section IV of this paper.
II. MATERIALS AND METHODS
In this section, we briefly described about the experimental datasets, feature extraction methods, balancing techniques and classification algorithm which are employed in this research. As shown in Figure 1 , the model consists of four main parts: drug-target data processing phase, feature extraction phase, balancing phase and model training phase. In the data processing phase, a drug is searched in the DrugBank [9] and ChEMBL [11] databases using their specific ID (e.g., DB00755) to collect the chemical structure in SMILE format. Analogously, a protein is searched in the KEGG [48] database using their specific ID (e.g., hsa:190) to collect the protein sequence in FASTA format. Before that, the drug ID and protein ID are both discovered from the KEGG database. In the feature extraction phase, three feature extraction techniques are used namely PSSM-Bigram, DP-PseAAC and AM-PseAAC to extract the protein sequences using the FASTA data, and the PubChem MSF technique is used to encode the drug chemical structure using the SMILE data. The training drug-target datasets are then constructed for the next phase. In the balancing phase, over-sampling SMOTE and random sampling technique are applied on the drug-target pair datasets to create the balanced experimental data. Finally, the XGBoost classifier is trained on the balanced datasets to construct our predictive model in the model training phase.
A. DRUG TARGET GOLD STANDARD DATASETS
To evaluate the proposed iDTi-CSsmoteB model, we have used four types of protein targets gold standard datasets namely, nuclear receptor, GPCR, ion channel and enzyme released by Yamanishi et al. [24] . These drug-target interaction datasets are extracted from DrugBank [49] , BRENDA [50] , KEGG BRITE [51] , and SuperTarget [52] . The gold standard datasets can be obtained directly from http://web.kuicr.kyoto-u.ac.jp/supp/yoshi/drugtarget/. According to the interactions among these drugs and targets, the number of known interaction pairs in each class are 90, 635, 1476 and 2926 respectively. Finally, we obtained total number of 5127 known interacting drug-target pairs. Table 1 shows the summary of drugs, targets, interactions and possible negative interactions of datasets. In our experiment, known drug-target interaction pairs are delineated as positive samples for four datasets. These drug-target datasets have been utilized in various research in the state-of-the-art methods [53] , [34] , [35] , [39] and also mentioned as benchmark gold datasets.
Drug-target interactions network is generally represented as a bipartite graph, where the nodes represent proteins or drugs and the edges represent known drug-target interactions between these nodes. The observation of the bipartite graph illustrates that it contains few edges that represent the real drug-target interactions which are approved by wet-lab experiments. For example, ion channel have total 210 × 204 = 42840 edges in the corresponding bipartite graph and only 1476 edges are known drug-target interactions (positive samples) from them. Therefore, the number of possible negative samples (42840 − 1476 = 41364) are significantly larger than the positive samples, creating biasness issue.
B. DRUG MOLECULES REPRESENTATION
To represent the structural information of a drug compound, a variety of molecular descriptors such as constitutional, topological, geometrical and quantum chemical properties have been developed. Furthermore, current studies indicate that the molecular substructure fingerprints can be an effective descriptor for representing drug compounds which is successfully applied for drug-target classification [35] , [46] problems. Here, the molecular compound is extracted through molecular substructure fingerprint (MSF) in a sequence of binary digits that demonstrate the presence or absence of individual substructure fragments or groups in the drug molecule. Additionally, it splits the drug molecule into a fixed number of fragments and represent the straight relationship among molecular structure and property. Each drug compound has a SMARTS list of substructure patterns [15] which is first indicated in the form of predefined dictionary. The drug substructure patterns and fingerprint bits have one-to-one corresponding relationship. In the substructure patterns, if a substructure is presented in the drug molecule, the corresponding substructure fingerprints are represented by 1 (presence), conversely, the absent substructures in the drug molecule are represented by 0 (absence). we utilized PyBioMed [54] , a highly customized and featurerich python library to evaluate different types of biological molecules, complex chemical and their interaction samples. The chemical structure of each drug in SMILES format is provided as input to the PyBioMed package and it is encoded in 881-dimensional binary feature vector based on PubChem fingerprints [55] .
C. TARGET PROTEINS REPRESENTATION 1) PSSM-BIGRAM PROBABILITIES
Position specific scoring matrix (PSSM) is an effective evolutionary information based feature extraction approach that can yield highly discriminatory nature for patterns (motifs) representation in protein sequences [56] . Recently, several studies disclosed that PSSM has been extensively exploited for dealing with different classification problems in bioinformatics [57] - [61] . In the PSSM matrix, the positive scores (large values) indicate high conserved position, and negative scores (small values) indicate weak conserved position of the query sequence [62] . A PSSM can be formulated as L × 20 matrix, where L (rows) indicates the length of the amino acid in inputted protein sequence, and 20 (columns) indicates total number of naive amino acids. Let's assume,
. , 20} and each matrix can be expressed as follows [56] :
Here, P i→j denotes the i-th position score of the amino acid residue in the protein sequence being substituted by the type j of 20 native amino acids, during the evolutionary process. The amino acids follow alphabetic order to represent their values (j = 1, . . . . . . , 20). In this study, PSI-BLAST [63] tool is used through Swiss-Prot database on server machine to generate the experimental M PSSM for each protein sequence which can be positive and negative integer values. We selected three iterations with the E-value of 0.001 to get the high homologous sequences. Consequently, we get the L × 20 scoring matrix.
The length of the values of a single protein sequence is different in PSSM matrix. Therefore, it is quite difficult to create a predictor for such PSSM matrix. For this reason, we transformed the PSSM matrix into identical length by using bigram probabilities descriptor, firstly proposed by Sharma et al. [64] for protein fold identification. The bigram probabilities descriptor can effectively handle the M PSSM matrix of different lengths and generate a fixed size of feature vector. The probability scores of j-th amino acid at i-th position in given protein sequence is calculated with 20 j=1 P i,j = 1 where i = 1, 2, . . . L;. Consequently, the bigram frequency of occurrence from m-th to n-th amino acid is represented as:
Equation (2) Here, the descriptor vector is defined by transpose T . The main advantage of pssm-bigram technique is avoiding zeros in the feature vector that is useful to increase the prediction accuracy.
2) AMPHIPHILIC PSEUDO AMINO ACID COMPOSITION (AM-PSEAAC)
AM-PseAAC is a combinational form of multidimensional vector and sequential information of protein, firstly introduced by Chou [65] . In the amino acid composition, a protein sequence is presented by multidimensional vector or discrete numbers where the sequence order facts is not considered in the process. On the other hand, AM-PseAAC contains both the multidimensional vector and sequence order information which has been intensively used for various protein functions [66] , [67] . The sequential form contains information regarding amino acid sequence order and length of a protein sequence. Let's assume, P is a protein with sequence length N . Therefore, we can define its amino acids residues as follows:
where A 1 indicates the 1st position of the amino acid residue in the protein sequence, A 2 specifies the 2nd position and so forth. In a protein, many helices are amphiphilic and VOLUME 7, 2019 different proteins provide different amphiphilic properties with different order patterns. The sequence-order information for each protein can be effectively normalized as follows:
In equation (5) N represents the length of a given protein. Where, 1 indicates the first rank correlation factor that represent the amino acids sequence order correlation among all the first-most adjacent residues; 2 indicates the second rank correlation factor that represent the amino acids sequence order correlation among all the second-most adjacent residues; and 2δ indicate the last rank correlations, respectively. Equations (4)- (5) illustrates that the amino acid residues information has been incorporated in the 2δ correlation factors. A set of 20 + 2δ is called the AM-PSeAAC descriptor. Here, the first 20 numbers represent the AAC and 2δ represents the amphiphilic correlation in a protein sequence. The AM-PseAAC descriptor is normalized as follows [65] :
where, F i denotes the normalized occurrence frequencies of i-th (i = 1, 2, . . . , 20) amino acid and the sequence order influence is indicated by the weight factor W . Finally, it generates 80-D feature vector for each protein sequence.
3) DIPEPTIDE PSEUDO AMINO ACID COMPOSITION (DP-PSEAAC)
Dipeptide composition (DPC) is one of the protein feature extraction methods to calculate the occurrence frequency of two respective contiguous amino acid residues [68] . It unitizes sequence neighborhood information and generates a fixed pattern length of 400-D feature vector for 20×20 amino acid composition (AAC) against a single protein sequence. For a protein sequence, the dipeptide composition is formulated as:
Here, M sr indicates the quantity of the dipeptides; s and r are the type of the amino acid in the protein sequence.
PseAAC is a combination of the conventional AAC and sequence-order information of a protein. Based on the concept of PseAAC, AAC (20) and dipeptide composition (400) are together considered as a feature extraction descriptor for protein features representation, containing feature vector of 420-D. DP-PseAAC comprises sequence order information, therefore, it represents the complete feature information with discrete models of a protein [69] , [70] . The output format of DP-PseAAC is: 1 st line-20 components of AAC; 2 nd line-20 components of DPC starting with amino acid A; . . . . ; 21 st line-20 components of DPC starting with amino acid Y.
D. BALANCING METHODS
As we mentioned earlier, the gold standard datasets are highly imbalanced and the classification samples are not evenly distributed. Therefore, different balancing approaches have been developed and utilized in the literature [56] , [71] where some methods modify (re-sampling) the minority class or majority class for adding new samples (oversampling) or deleting redundant samples (under-sampling) whereas others employ balancing weight in the original datasets. In this study, we applied random under sampling and over-sampling SMOTE techniques to manage the imbalanced datasets and created the drug-target training datasets. The random under sampling adds negative samples from the non-interacting space until the size of the negative samples are roughly equal to the positive samples [15] , [72] . Our second experimental datasets are constructed using the over-sampling SMOTE which can syntactically generate positive samples of the experimental datasets to balance the minority class and enhance the prediction efficiency of the classifier [68] , [73] .
Based on the number of the required oversampling, SMOTE takes initiative to create extra hypothetical positive training drug-target data in the minority class along the line segments that attaches any/all the 'k' nearest neighbors [74] . The SMOTE samples are generated from the linear combination of two similar minority classes (y i andŷ i ) and are represented as [68] :
With 0 ≤ δ ≤ 1, y n represents the synthetic new samples and y i denotes the randomly selected samples of the i-th sample from the minority class datasets where i = 1, 2, 3, . . . , T . y i is the nearest neighbor data and δ represents a random number. A new synthetic sample is generated by the randomized interpolation using equation (8) . The detailed instructions of SMOTE is as follows:
(i) Randomly select sample and find the K-nearest neighbors for every minority class sample from the minority class datasets. 
F. CLASSIFICATION ALGORITHM
Extreme Gradient Boosting (XGBoost) is a highly optimized ensemble algorithm, introduced by Chen Tianqi [75] in recent years. XGBoost has been extensively applied for regression and classification challenges [76] , [77] by data scientists to obtain the best performance in data mining and machine learning fields, particularly in kaggle. It's a scalable tree boosting method that follows the same decision rules as the gradient tree boosting algorithm [78] where regularized objective is minor changed to extend the efficiency of the model. For a dataset, the prediction results are the sum of the predicted scores of the k trees, as shown in equation (9):
where, x i represents the i-th drug-target sample of the training datasets, f k (x i ) is the value of k-th tree and all the decision trees values are represented by function F. In this model, the regularized objective is minimized to learn the functions. The regularized objective function is formulated as follows:
where, l is the loss function that determine the compatibility of the model for each training dataset;ŷ i indicates the prediction and y i indicates the target. The second item is responsible for penalizing the complexity of the training tree functions. The additional regularized objective helps to choose the predictive functions and control the complexly of the model. More importantly, it also handles the overfitting issue. The penalized complexity formula for our model is shown in formula (11):
where, λ and γ refer the constant coefficients, γ represents the value of each leaf, and T represents the total number of leaves in the regression tree. This is an additive manner model, therefore, a new tree is added in the model each time where the prediction score is equal to the combined score of the previous tree and new tree. To remove the constant item and enhance the loss function, second order Taylor expansion is applied in the gradient boosting process. Suppose, I j = {i|q (x i ) = j} is a set of leaf j. Since equation (10) is not enough to optimize the model, f t is greedily added to the equation in order to enrich the model. The final objective function with the t-th tree is formulated as follows:
where, g i = ∂ˇy(t−1)l(y i ,y represents the second order gradient statistics of the loss function. Here, we can compress the mathematical expression by defining A j = i∈I j g i and B j = i∈I j h i . From a tree structure q (x), the optimal weight ω * j and the corresponding optimal values can be calculated using the following formulas:
After the tree split, the loss reduction from the leaf nodes can be by computed the following formula in full form:
where, I L and I R are the left and right nodes of the instance sets, respectively. We can obtain the best split from any node, and the results depend on the regularization parameter γ and the loss function.
III. RESULTS AND DISCUSSION
In this section, we explain the experimental results of our method for predicting DTIs. We implemented all the methods i.e., features extraction techniques, balancing methods, classification algorithms of the proposed predictor in Python language (Python 3.6 version) using Scikit-learn library, PyBioMed library, imbalanced-learn API and XGBoost python package. All the implantations and experiments were VOLUME 7, 2019
performed on a high performance computer provided by the Computational Intelligence Lab, UESTC. For experimental purposes, two important aspects have been considered: (i) choosing the evaluation metrics (section A) to measure the prediction performance, and (ii) conducting different types of experiments (section B-E) to obtain the values of the metrics.
In the experiments part, we analyzed the effectiveness of different feature extractions techniques, classifiers, balancing methods used in this research. Finally, we make comparison of our proposed iDTi-CSsmoteB method against other similar methods.
A. EVALUATION METRICS
Several performance metrics have been employed to evaluate the prediction capability of the predictor model. Let's assume, P denotes the number of positive drug-target samples and N donates the number of negative drug-target samples in the datasets. Let, TP (true positive) is the total amount of interacting drug-target samples and TN (true negative) is the total amount of non-interacting drug-target samples predicted by the classifier. Similarly, FP (false positive) indicates the number of non-interacting drug-target samples predicted incorrectly as interacting drug-target pairs and FN (false negative) indicates the number of interacting samples predicted incorrectly as non-interacting samples by the classifier. Afterwards, the performance metrics, including accuracy (Acc), sensitivity (Sen), specificity (Spe), MCC and F1 Score has been computed accordingly using the following formulas:
The benchmark datasets applied for DTIs in the literature are largely imbalanced, therefore, we have utilized another effective measures called AU receiver operating characteristic (auROC) curve for evaluating the classification performance of our method. A ROC curve is a plot of sensitivity or true positive rate versus 1-specifcity or false positive rate for different threshold values. Generally three crossvalidation techniques of sampling namely sub-sampling (k-fold cross validation), holdout method and jackknife tests are used for the evaluation of prediction performance and quality [79] . Among these techniques, the k-fold cross validation has been extensively employed by the researchers since it always shows distinguished characteristics. Accordingly, 5-fold cross validation procedure was adopted to estimate the performance of the predictor in this research. During the cross validation process, the drug-target datasets are randomly separated into five folds with approximately same size where four folds are defined as the training samples and remaining one fold is used as the testing samples. Most importantly, the training pairs and testing pairs does not have any overlapping samples in any round of 5-fold cross-validation. Moreover, the whole method is executed five times and the prediction results of the datasets are calculated for each part. Finally, the average of the cross-validation measures the prediction performance and considered as the final prediction results. Since, the oversampling SMOTE technique is executed during the 5-fold cross-validation process, the original dataset is first splitted into training samples and testing samples. SMOTE is then applied on the training samples in each round of cross validation [80] , i.e., only the training samples are oversampled. In this case, the testing samples are not oversampled, and completely unseen by the predictive model. Afterwards, the model is performed on the testing samples which doesn't have any synthetic data.
B. EFFICIENCY OF DIFFERENT FEATURE GROUPS
We performed a series of comparative experiments using four individual feature descriptors to analyze the effects of various feature groups for different classification algorithms. Each individual protein feature descriptor is combined with a fixed drug molecular substructure fingerprint (MSF) descriptor and creates a drug-target feature group which is already reported in Table 2 . The first feature group, namely, MSF+PSSM-Bigram, contains 1281 features and other two feature groups, namely, MSF+AM-PseAAC and MSF+DP-PseAAC, contains 961 and 1301 features, respectively. For these experiments, the random sampling method is used as a balancing method to prepare the datasets for training our model. Table 3 shows the prediction performance of these three feature groups for various classification algorithms on the four datasets.
Among all the experimental datasets, MSF+PSSM-Bigram feature group obtained significant prediction performance than MSF+DP-PseAAC and MSF+AM-PseAAC for the enzyme and ion channel datasets. We clearly see from Table 3 that all the three feature groups achieved best results for enzyme dataset, followed by ion channel, GPCR and nuclear receptor. However, nuclear receptor dataset provided most unrhymed results for different feature groups where MSF+DP-PseAAC achieved slightly higher results than the others. From these experiments, we have achieved the performance values for individual feature groups and various combinational feature groups as well. Here, the highest auROC values were found when the protein PSSM-Bigram features were combined with drug MSF. Furthermore, the enzyme dataset shows the best performance for the drug-protein feature groups whereas the model obtained highest auROC of 0.9684 for MSF+PSSM-Bigram, indicating the influence of the evolutionary information and structural properties. This feature group also shows comparatively similar performance for the ion channel and GPCR for the XGBoost classifier in terms of auROC. Moreover, in most cases, the auROC values were increased when the MSF descriptor was added with the PSSM-Bigram. The rise in the auROC values clearly depicts the efficiency of the evolutionary based features. Random Forest classifier is slightly higher than XGBoost classifier for nuclear receptor dataset for MSF+DP-PseAAC and MSF+AM-PseAAC feature groups. However, the circumstance is in favor of the XGBoost classifier for enzyme, ion channel and GPCR datasets for all the feature groups. The objective of the experiment is to investigate and compare the efficiency of various feature groups with different classifiers and disclose the effective feature groups for the four datasets. The results of these experiments confirm that PSSM-Bigram descriptor is more informative and plays a significant role to predict drug-target interaction than DP-PseAAC and AM-PseAAC descriptors. More experimental findings can be found in the supplementary document (supplementary file I).
C. EFFICIENCY OF THE XGBOOST CLASSIFIER
To further evaluate the effectiveness of our iDTi-CSsmoteB model, we have selected four suitable classifiers namely, XGBoost [75] , Random Forest [81] , Logistic Regression [82] and Support Vector Machine [83] for the experiments. After obtaining the predicted auROC value for each classifier, the prediction performances have been compared within all the four classifiers using the same feature groups on enzyme, ion channel, GPCR and nuclear receptor datasets. The random under sampling technique has been utilized to handle the data imbalance problem to create the training datasets in this phase. Table 3 contains the prediction results of different classifiers regarding auROC for the four datasets. As shown in Table 3 , the XGBoost classifier archived highest auROC value of 0.9684 on the enzyme dataset, on the other hand, second highest auROC value of 0.9412 was obtained through Random Forest classifier. Similarly, on the ion channel dataset, highest auROC value of 0.9642 was archived by the XGBoost classifier and second highest auROC value of 0.9190 was obtained by the Random Forest classifier. It is observed that XGBoost consistentlyacquired effective prediction values compared to Random Forest, Logistic Regression and SVM for most of the feature groups including individual and combinatorial feature groups (also see supplementary file I). The ROC curves for the MSF+PSSM-Bigram feature group for different classifiers are illustrated in Figure 3 . We can clearly see that the ROC curves, generated by the XGBoost is significantly higher than the other classifiers.
Within the 12 dataset-feature groups, XGBoost provides better auROC values for 10 dataset-feature groups and other 2 highest auROC values were achieved by Random Forest for nuclear receptor dataset. It can be concluded from these results that XGBoost is the most suitable classifier among the considered four classifiers. Therefore, we set XGBoost classifier for our iDTi-CSsmoteB model that might become a very effective and useful prediction model for identifying DTIs on large scale datasets.
D. EFFICIENCY OF THE BALANCING TECHNIQUES 1) RANDOM SAMPLING
The efficiency of the random sampling technique using XGBoost classifier with different feature groups are demonstrated in this section. Each feature group was evaluated using effective XGBoost classifier over 5-fold cross validation. Table 4 shows the prediction performance of different feature groups on the four datasets and the respective roc curves are displayed in figure 4 . Using the enzyme dataset, the iDTi-cssmoteb obtained AUC values Table 4 . We can summarize the perceptions from the above discussions as: Firstly, structural information, evolutionary information and sequence information of drug-target can achieve significant performance with random sampling technique for our model. Compared to MSF+DP-PseAAC and MSF+AM-PseAAC feature groups, the MSF+PSSM-Bigram feature group showed highest and reliable prediction performance which has significant impact on detecting DTIs, verified by these experiments. Secondly, XGBoost constantly obtained better prediction for all three feature groups.
2) OVER-SAMPLING SMOTE
The subsequent experiments have been implemented to investigate the efficiency of the SMOTE technique. The results of different feature groups using XGBoost classifier are listed in Table 5 Table 5 . In order to compare the efficiency of the two balancing methods, we illustrate the ROC curves generated with MSF+PSSM-Bigram feature group using random sampling and oversampling SMOTE in Figure 5 .
We can summarize several observations from the above discussion: Firstly, the over-sampling SMOTE significantly outperforms the random sampling method in case of ROC curves on all of the datasets. Secondly, we can analytically demonstrate that the performance of the XGBoost classifier have been increased after applying the over-sampling SMOTE (also see supplementary file II) and MSF+PSSM-Bigram is still the significant feature group among all the feature groups. More specifically, the performance significantly increases for all the datasets in case of specificity and MCC metrics which has lower performance values for random sampling. Thirdly, over-sampling SMOTE is the suitable balancing technique in this study to predict DTIs, since it increases the prediction performance and reduces the model biasness for all the four datasets, especially the nuclear receptor dataset.
3) COMBINED FEATURE GROUPS FOR RANDOM SAMPLING AND OVER-SAMPLING SMOTE
To acquire the benefit of all the feature extraction techniques, combined feature groups were constructed by taking different combinations of single feature extraction techniques. This combined feature groups are created using four individual drug and protein feature techniques including MSF, PSSMBigram, DP-PseAAC and AM-PseAAC. After combining, the dimension of a feature group is increased to 1781-D (881+400+80+420). In order to evaluate the performance of the combined feature groups, we have applied XGBoost classifier with random sampling and over-sampling SMOTE techniques using four datasets. Table 6 shows the performance results of the model and their respective ROC curves are exhibited in Figure 6 . The prediction results demonstrate that the performance changing strategy from random sampling to over-sampling SMOTE of all the evaluation metrics for nuclear receptor dataset is noteworthy, where the AUC value is jumped to 0.9350 from 0.8611. Among the four drugtarget datasets, enzyme has obtained the highest AUC values for both data balancing techniques, which is 0.9607 for random sampling and 0.9830 for oversampling SMOTE, respectively. Moreover, the prediction performance of the highest combined feature groups (e.g. MSF+PSSM-Bigram+DP-PseAAC+AM-PseAAC) is slightly lower than the individual feature groups (e.g. MSF+PSSM-Bigram) in most of the cases (supplementary file II). However, some of combined feature groups show almost similar performance as individual feature groups for oversampling SMOTE and few of them achieved higher results for random sampling. In conclusion, we can say that the overall performance for oversampling SMOTE is higher than random sampling, for all the four datasets. Because of the high dimensional features and long execution time, the computing expense and complexity of the individual feature groups are less than that of combined feature groups. In this circumstances, it is absolutely effective to consider individual feature group instead of combining them.
E. COMPARISON WITH EXISTING METHODS
As mentioned earlier, various supervised learning methods for predicting DTIs have been employed in the literature. In order to illustrate the effectiveness of iDTi-CSsmoteB, we compared it with seven state-of-the-art methods by using the auROC values as the key performance metric for the same benchmark gold standard datasets. Moreover, these existing methods adopted 5-fold cross validation on the four datasets as well. We have compared the average auROC values of iDTi-CSsmoteB with that of Rayhan et al. [45] , Huang et al. [43] , Wang et al. [84] , Mousavian et al. [35] , Yamanishi et al. [39] , NetCBP [27] and Li et al. [46] . Table 7 reported the auROC values for all the compared methods along with our proposed method iDTi-CSsmoteB. We can clearly see that the performance of iDTi-CSsmoteB is significantly better than the seven state-of-the-art methods in term of auROC. The average auROC values of our developed predictor on the enzyme, ion channel, GPCR and nuclear receptor datasets are 0.9860, 0.9838, 0.9592 and 0.9459, respectively. This high prediction performance has been achieved due to our novel feature extraction methods for drug molecules and proteins which encodes highly discriminative information. Moreover, the use of over-sampling SMOTE balancing technique nicely handles the imbalance issues of the datasets with our powerful XGBoost classifier, demonstrating the best performance for predicting DTIs.
F. WEB SERVER IMPLEMENTATION
To enhance the importance of DTIs real implementation, a separate web server has been developed for iDTi-CSsmoteB at the website http://idticssmoteb-uestc.me/.
This web server's main intension is to acquire desired results for scientific usage by providing simple mechanisms and friendly user interface. Users first need to choose any of the benchmark gold datasets i.e. nuclear receptor, GPCR, ion channel and enzyme as a target type. After that, the drug ID (e.g., D00021) needs to be selected from the drop down list to generate the MSF features from drug SMILE format. For a specific drug ID, the respective protein IDs (e.g., has:10056) will be loaded automatically in the protein ID drop down list. After selecting the protein ID, it requires to select specific protein feature extraction method. Here, our system generates PSSM-Bigram/DP-PseAAC/AM-PseAAC from protein FASTA format. These drug and protein features can conveniently be generated using python language and PyBioMed python library. After loading the drug and respective protein extraction features, click on the submit button to get the prediction probabilities results. Moreover, user can choose the drug and protein features from the Example files for predicting DTIs. Our web server also provides a step by step user guidelines.
IV. CONCLUSION
In this article, an intelligent computational method called, iDTi-CSsmoteB, has been proposed to predict the DTIs using evolutionary information, sequence information and structural properties. Based on our knowledge, none of the previous research focused on sequence information based feature extraction methods of protein, for predicting DTIs. Afterwards, individual drug and protein feature groups are merged into combined feature groups to construct our datasets. To handle the biasness issue and construct high throughput predictor, it applies the SMOTE technique and XGBoost classifier. Several experiments have been performed on four benchmark gold datasets in a wide scale to measure and investigate the prediction performance of iDTi-CSsmoteB. Notably, iDTi-CSsmoteB has achieved highest average auROC values in comparison with the stateof-the-art methods by performing 5-fold cross validation. This significant achievement is imposed with novel feature extraction techniques, SMOTE technique and XGBoost classifier. It demonstrates that the findings of our proposed model will enrich the future research especially in the drug-target interaction area. Moreover, it can farther be potentially helpful for protein sequence information based prediction and imbalanced issues of datasets. Area under Precision Recall (auPR) curve is also an effective measurement metric for imbalanced datasets to compare the performance, which have been argued in the literature. In future, we shall consider a semi-supervised learning technique with auPR matric for our model. He is currently pursuing the Ph.D. degree in computer science and technology with the Nanjing University of Science and Technology and a member of the Pattern Recognition and Bioinformatics Group. He has published several papers in reputed journals. His current research interests include machine learning, bioinformatics, and computational biology.
